ERBB2/HER2/CD340 Antibody

• Catalog Number: orb1806342
• Category: Antibodies
• Description: Anti-ERBB2 / HER2 / CD340 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 143.9 kDa.
• Target: ERBB2 / HER2 / CD340
• Clonality: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human, Monkey, Mouse
• Concentration: Batch dependent
• Buffer/Preservatives: 100 mM Proline/Acetic acid 20mM Arginine pH 5.0
• Purity: >95%
• Purification: Protein A
• UniProt ID: P04626
• MW: 145.44 kDa
• Tested applications: ELISA, FA, FACS, In vivo
• Expression System: CHO
• Endotoxins: <0.001 EU/ug
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Note: For research use only

Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab)is more than 99.02% ;determined by SEC-HPLC.

Immobilized human HER2(23 652) His at 2 μg/mL can bind Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab);EC50=0.01375μg/mL.

BT474 cells were stained with Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC98=0.2994 μg/mL.

Pertuzumab+trastuzumab inhibited the tumor growth of NCI-N87 on Balb/c nude mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 73.8% at 5 mpk at D37.